Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets

被引:48
作者
Riachy, R
Vandewalle, B
Belaich, S
Kerr-Conte, J
Gmyr, V
Zerimech, F
d'Herbomez, M
Lefebvre, J
Pattou, F
机构
[1] Fac Med, UPRES 1048, Lab Endocrinol Expt, F-59045 Lille, France
[2] CHR, Nucl Med Lab, Lille, France
关键词
D O I
10.1677/joe.0.1690161
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined whether 1,35 dihydroxyvitamin D-3 (1,25 D-3), the active form of vitamin D involved in the regulation of the immune system, may also protect human pancreatic islet cells from destruction induced by cytokines. III this study, we specifically investigated the effect of 1,25 D, oil oxidative stress and major histocompatibility complex (MHC) induction, both implicated III cytokine-induced islet cell dysfunction and destruction. We also investigated the effects of 1,25 D, on interleukin (IL)-6, a pleiotropic cytokine implicated in the pathogenesis of immunoinflammatory disorders. Human pancreatic islets, isolated from heart-beating donors, were treated with a combination of three cytokines, IL-1 beta +tumor necrosis factor alpha +interferon gamma, in the presence or absence of vitamin D, and compared with with untreated control cells. Metabolic activity was assessed by cell viability and insulin content. Oxidative stress was estimated by heat shock protein 70 (hsp70) expression, cell manganese superoxide dismutase (MnSOD) activity and nitrite release, a reflexion of nitric oxide (NO) synthesis. Variation of immunogenicity of islet preparations was determined by analysis of the MHC class I and class II transcripts. Inflammatory status was evaluated by IL-G production. After 48 h of contact with cytokines, insulin content was significantly decreased by 40% but cell viability was not altered. MHC expression significantly increased six- to sevenfold as well as NO and IL-6 release (two- to threefold enhancement). MnSOD activity was not significantly induced and hsp70 expression was not affected by the combination of cytokines. The addition of 1,25 D-3 significantly reduced nitrite release, IL-6 production and MHC class I expression which then became not significantly different from controls. These results suggest that the effect of 1,25 D-3 in human pancreatic islets cells may be a reduction of the vulnerability of cells to cytotoxic T lymphocytes and a reduction of cytotoxic challenge. Hence, 1,25 D-3 might play a role in the prevention of type 1 diabetes and islet allograft rejection.
引用
收藏
页码:161 / 168
页数:8
相关论文
共 54 条
[11]   NF-κB is required for cytokine-induced manganese superoxide dismutase expression in insulin-producing cells [J].
Darville, MI ;
Ho, YS ;
Eizirik, DL .
ENDOCRINOLOGY, 2000, 141 (01) :153-162
[12]   Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells [J].
Delaney, CA ;
Pavlovic, D ;
Hoorens, A ;
Pipeleers, DG ;
Eizirik, DL .
ENDOCRINOLOGY, 1997, 138 (06) :2610-2614
[13]   Beta-cell defence and repair mechanisms in human pancreatic islets [J].
Eizirik, DL .
HORMONE AND METABOLIC RESEARCH, 1996, 28 (06) :302-305
[14]   CYTOKINES SUPPRESS HUMAN ISLET FUNCTION IRRESPECTIVE OF THEIR EFFECTS ON NITRIC-OXIDE GENERATION [J].
EIZIRIK, DL ;
SANDLER, S ;
WELSH, N ;
CETKOVICCVRLJE, M ;
NIEMAN, A ;
GELLER, DA ;
PIPELEERS, DG ;
BENDTZEN, K ;
HELLERSTROM, C .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) :1968-1974
[15]   Cytokines activate the nuclear factor kappa B (NF-kappa B) and induce nitric oxide production in human pancreatic islets [J].
Flodstrom, M ;
Welsh, N ;
Eizirik, DL .
FEBS LETTERS, 1996, 385 (1-2) :4-6
[16]  
FLOHE L, 1984, METHOD ENZYMOL, V105, P93
[17]   ABERRANT EXPRESSION OF CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES BY B-CELLS AND HYPEREXPRESSION OF CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES BY INSULIN CONTAINING ISLETS IN TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS [J].
FOULIS, AK ;
FARQUHARSON, MA ;
HARDMAN, R .
DIABETOLOGIA, 1987, 30 (05) :333-343
[18]   INVIVO BENEFICIAL-EFFECTS OF CYCLOSPORINE A AND 1,25-DIHYDROXYVITAMIN-D3 ON THE INDUCTION OF EXPERIMENTAL AUTOIMMUNE-THYROIDITIS [J].
FOURNIER, C ;
GEPNER, P ;
SADOUK, M ;
CHARREIRE, J .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1990, 54 (01) :53-63
[19]  
Hahn HJ, 1997, TRANSPLANT P, V29, P2156
[20]  
Hattori M, 1990, Nihon Jinzo Gakkai Shi, V32, P147